Navigation Links
Poniard Pharmaceuticals Announces Promising Data From Interim,Safety Analysis of Phase 1 Combination Trials of Picoplatin in,Colorectal and Prostate Cancers

les either in combination with docetaxel for prostate cancer or with 5-fluorouracil and leucovorin for colorectal cancer. We anticipate that the Phase 2 trials for both indications will begin in the third quarter of 2007, shortly after the maximum tolerated doses have been defined."

He added, "In the Phase 1 colorectal cancer study, only three patients have experienced grade 1 neuropathy to date. There has been no neuropathy greater than grade 1 in all patients treated, including four patients who have received a cumulative picoplatin dose of greater than 900 mg/m2. The objective of our planned Phase 2 trial is to confirm the neuropathy-sparing properties of picoplatin given once every two weeks in a randomized trial compared to oxaliplatin and to enable a Phase 3 clinical trial to show superior safety and efficacy of FOLPI (picoplatin combined with fluorouracil and leucovorin) compared to FOLFOX (oxaliplatin combined with fluorouracil and leucovorin). The goal of our planned Phase 2 study in prostate cancer is to generate proof-of-concept data demonstrating that picoplatin has improved efficacy with docetaxel and to enable future picoplatin combination studies with taxanes for prostate and other cancer indications."

Phase 1 CRC Trial Data

The Phase 1 component of the CRC trial was designed to identify the maximum tolerated dose of picoplatin administered every two or four weeks with fluorouracil and leucovorin administered every two weeks. The starting dose of picoplatin for the every-two-week regimen was 45 mg/m2. In subsequent cohorts, picoplatin was increased by 15 mg/m2. The starting dose of picoplatin for the every-four-week regimen was 60 mg/m2. In subsequent cohorts, picoplatin was increased by 30 mg/m2 until dose-limiting toxicity established the maximum tolerated dose.

To date, 40 patients have been treated and have received up to 10 months of therapy. Therapy has been well tolerated with infrequent dose delays because of non-cu
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Poniard Pharmaceuticals Announces Clinical Data from Picoplatin Phase 2 Small Cell Lung Cancer Trial To Be Presented at American Society of Clinical Oncology Annual Meeting
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
Post Your Comments:
(Date:5/17/2013)... Conn. , May 17, 2013 /PRNewswire-iReach/ -- ... and recombinant proteins, is placing renewed emphasis on ... the rise as a number of factors are ... for pharmaceutical makers and their delivery device partners ... previously refractory conditions, the growing trend toward self-administration ...
(Date:5/17/2013)... 17, 2013  Boehringer Ingelheim will contribute to ... the American Thoracic Society International Conference (ATS 2013) ... 17 – 22. Data will highlight ... treatment of chronic obstructive pulmonary disease (COPD) [Spiriva® ... investigational compounds for asthma, idiopathic pulmonary fibrosis (IPF) ...
(Date:5/17/2013)... (EURONEXT: SAN and NYSE: SNY ) announced today ... examining the selective JAK2 inhibitor SAR302503 for myelofibrosis (MF), ... primary endpoint assessed the proportion of patients achieving >/=35% ... previous trials, the most common adverse events were anemia, ... at an upcoming medical congress. MF ...
Breaking Medicine Technology:Pharmaceutical Makers and Delivery Device Partners Rethink Delivery Technologies - New Report Examines this Evolving Segment 2Pharmaceutical Makers and Delivery Device Partners Rethink Delivery Technologies - New Report Examines this Evolving Segment 3Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 2Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 3Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 4Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 5Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 6Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 7Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 8Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 3Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 4Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 5Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 6
(Date:5/19/2013)... 19, 2013 The legal team at ... in a concerted effort to connect women and families ... control drugs Yaz, Yasmin & Ocella with the legal ... information on the notorious birth control drugs as well ... , Yaz, Yasmin & Ocella were very popular ...
(Date:5/18/2013)... 18, 2013 Daily Gossip issued a press ... review on their page. John Colston, Daily Gossip’s spokesperson, told ... Hadsall’s revolutionizing 14-Day Rapid Fat Loss Plan . ... carbs are healthy at a time when nutritionists and fat ... caloric products. , The diet is based on the ...
(Date:5/18/2013)... Also known as bariatric surgery , ... surgery that guarantees patients long-term weight loss. Dr. Naim ... give readers a brief tutorial on this revolutionary weight ... New York City’s Mount Sinai School of Medicine. After ... fellowship in Minimally Invasive Bariatric Surgery. He has also ...
(Date:5/18/2013)... Children who swallow high-powered magnets often need surgery and ... a new study. The researchers, from the Louisiana ... more than 79 percent of children who swallowed very ... procedure, in which a tube containing a camera is ... these cases can be treated through observation or by ...
(Date:5/18/2013)... FL (May 18, 2013) There are significant ... commonly used to diagnose or treat gastrointestinal problems, ... (DDW). , A study by New York ... more objective testing may substantially reduce the cost ... Although GERD is believed to affect nearly 25 ...
Breaking Medicine News(10 mins):Health News:Yazsideeffects.com Connects Yaz Side Effects Sufferers With Yaz Side Effects Lawyers 2Health News:Everything You Need to Know About Lap Band Surgery 2Health News:Everything You Need to Know About Lap Band Surgery 3Health News:Swallowing Magnets Can Be Fatal for Children 2Health News:New research identifies practice changes to improve value and quality of GI procedures 2
... to keep smoking, experts say , TUESDAY, June 15 (HealthDay News) ... a B vitamin are half as likely as others to develop ... doesn,t mean that smokers should hit the vitamin aisle instead of ... as one amino acid, to fewer cases of lung cancer, it ...
... a unanimous decision, the Florida Advisory Council on Radiation ... Radiation Oncology,s (ASTRO) patient protection plan. , ASTRO,s Board ... of the Society,s patient safety and quality assurance projects, ... January 28-31, 2010. The goal of the plan is ...
... The Sixth Book in ... the 21st Century and Presents the Essence and Secrets of Ancient Teachings of Tao Along ... , ... the newly released sixth book of his best-selling Soul Power Series, Tao I: The Way of ...
... book by researchers at Oregon State University uses the snapshot-in-time ... types of animal and plant fossils not just what ... behaved, especially at the moment of death. All kinds ... mating and reproductive instincts, to the behavior of pathogenic microbes ...
... ... calves by kayak and and view them just a few meters from ... is a national park, UNESCO World Heritage Site, and the only calving ... camping, whale watch cruise and van tour of the peninsula,s unique wildlife, ...
... found cases missed by routine screening, researchers say , TUESDAY, ... the methods for early detection of HIV, researchers sought to ... increase the number of cases that could be detected early, ... Nucleic acid tests look for traces of genetic material from ...
Cached Medicine News:Health News:Vitamin B6 Tied to Lowered Lung Cancer Risk 2Health News:Vitamin B6 Tied to Lowered Lung Cancer Risk 3Health News:Florida radiation council endorses ASTRO patient protection plan 2Health News:TAO l: The Way of All Life, by Zhi Gang Sha Reaches #6 on New York Times Bestseller List 2Health News:TAO l: The Way of All Life, by Zhi Gang Sha Reaches #6 on New York Times Bestseller List 3Health News:A new view of fossils: The behavior of ancient life forms 2Health News:Kayak With Whales Argentina Patagonia - From Our Exclusive Beach Camp 2Health News:Gene-Based Detection Method Might Spot HIV Earlier 2
Straight shafts with two point fixation. Tips separated by 3 mm, each tip has 0.12 mm, 1 x 2 teeth. Wide serrated handle with dull finish....
Curved shafts with 0.5 mm, 1 x 2 teeth. Serrated handle with thumb catch lock and polished finish....
5 mm jaws with teeth provide secure fixation of occular structures....
Straight shafts with fine Pierse type tips. Flat smooth handle with dull finish....
Medicine Products: